Patient Population Under Consideration
This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care
clinician with vision problems.
Suggestions for Practice Regarding the I Statement
Potential Preventable Burden
In 2011, about 12% of US adults aged 65 to 74 years and 15% of those 75 years or older reported having problems
seeing, even with glasses or contact lenses.1
The prevalence of AMD is 6.5% in adults older than 40 years and increases with age (2.8% in those aged 40–59
years and 13.4% in those aged ≥60 years).2
About half of all cases of bilateral low vision (ie, best-corrected visual acuity of <20/40) in adults 40 years
and older are caused by cataracts. The prevalence of cataracts increases sharply with age; an estimated 50% of US
adults 80 years or older have cataracts.1
The prevalence of hyperopia requiring a correction of +3.0 diopters or more ranges from about 5.9% in US adults aged
50 to 54 years, to 15.2% in adults aged 65 to 69 years, to 20.4% in adults 80 years or older.1
Older age is an important risk factor for most types of visual impairment. Additional risk factors for cataracts are
smoking, alcohol use, ultraviolet light exposure, diabetes, corticosteroid use, and black race. Risk factors for AMD
include smoking, family history, and white race.1
Potential Harms
The harms of screening in a primary care setting have not been adequately studied. Overall, the potential for harms
from treatment are small to none. Harms of treatment of refractive error include a potential for increased falls
with the use of multifocal lenses; infectious keratitis with the use of contact lenses, laser-assisted in situ
keratomileusis (LASIK), or laser-assisted subepithelial keratectomy (LASEK); and corneal ectasia with LASIK. Harms
of cataract surgery include posterior lens opacification and endophthalmitis. Treatment of AMD with antioxidant
vitamins and mineral supplements is not associated with increased risk of most serious adverse events.
Although there appears to be benefit in longer-term outcomes, a systematic review found that treatment of AMD with
laser photocoagulation was associated with greater risk of acute loss of 6 or more lines of visual acuity vs no
treatment at 3 months (relative risk [RR], 1.41 [95% CI, 1.08–1.82]).3
Pooled estimates report a non–statistically significant association bewteen photodynamic therapy and risk of
acute loss of 20 or more letters of visual acuity vs placebo at 7 days (RR, 3.75 [95% CI, 0.87–16]) (3
trials).4, 5
One of 2 trials found that treatment of wet AMD with intravitreal vascular endothelial growth factor (VEGF)
inhibitor therapy was associated with greater likelihood of withdrawal vs sham therapy; there were no differences in
serious or other adverse events, but estimates were imprecise.1, 4, 6, 7
Current Practice
About half of US adults older than 65 years reported having an eye examination within the last 12 months in a 2007
study.8
Screening Tests
A visual acuity test (eg, the Snellen eye chart) is the usual method for screening for visual acuity impairment in
the primary care setting. Screening questions are not as accurate as visual acuity testing for identifying visual
acuity impairment. Evidence on the use of other tests for vision screening in primary care, such as the pinhole test
(a test for refractive error), the Amsler grid (a test of central vision to detect AMD), genetic testing, or
funduscopy (visual inspection of the interior of the eye), is lacking.
Treatment
Several types of treatment are effective for improving visual acuity. Corrective lenses improve visual acuity in
patients with a refractive error. Treatment of cataracts through surgical removal of the cataract is effective for
improving visual acuity. Treatment of exudative (or wet) AMD includes laser photocoagulation, verteporfin, and
intravitreal injections of VEGF inhibitors. Antioxidant vitamins and minerals are an effective treatment for dry
AMD.
Other Approaches to Prevention
This recommendation statement does not include screening for glaucoma. The USPSTF’s recommendations on
screening for glaucoma and falls prevention are available on its website (www.uspreventiveservicestaskforce.org).